Atlantic Equities Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $490
Atlantic Equities analyst Steve Chesney maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $500 to $490.
IDEXX Laboratories Misses on Q2 Earnings, Issues FY22 Guidance Below Consensus
IDEXX Laboratories Inc (NASDAQ:IDXX) reported Q2 revenues of $861 million, an increase of 4% Y/Y on a reported basis and…
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell
• Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
$1000 Invested In This Stock 15 Years Ago Would Be Worth $3,700 Today
IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 15 years by 1.93% on an annualized basis producing an average annual return of 9.0%. Currently, IDEXX Laboratories has a market capitalization of $33.34 billion.
Where IDEXX Laboratories Stands With Analysts
Analysts have provided the following ratings for IDEXX Laboratories (NASDAQ:IDXX) within the last quarter:
How Is The Market Feeling About IDEXX Laboratories?
IDEXX Laboratories's (NASDAQ:IDXX) short percent of float has risen 7.34% since its last report. The company recently reported that it has 1.95 million shares sold short, which is 2.34% of all regular shares that are available for trading.
4 Analysts Have This to Say About IDEXX Laboratories
Over the past 3 months, 4 analysts have published their opinion on IDEXX Laboratories (NASDAQ:IDXX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Stifel Maintains Buy on IDEXX Laboratories, Lowers Price Target to $500
Stifel analyst Jonathan Block maintains IDEXX Laboratories (NASDAQ:IDXX) with a Buy and lowers the price target from $575 to $500.